PRACTICE Guidelines REGISTRATION PLATFORM

News MORE

2023.0306

The Development of Reporting Guideline of clinical Practice Guidelines in General Practice

The Development of Reporting Guideline of clinical Practice Guidelines in General Practice provides detailed guidance for the makers and writers of the general practice guidelines, which will further improve the reporting quality of the general practice guidelines, especially the Chinese general practice guidelines, and promote the application in general medical practice, thus finally improving the quality of primary medical care.

2023.0220

Guidelines should consider clinician’s time needed to treat

Professor Gordon Guyatt of McMaster University and Professor Victor Montori of the Mayo Clinic jointly published a paper in the British Medical Journal (BMJ) entitled: Guidelines should consider clinicians' time needed to treat on January 3, 2023.

2022.1126

The International Guideline Evaluation Screening Tool (IGEST): Development and Validation

IGEST is a generic tool for screening guidelines for any specialty, target population, and healthcare organization, but it is intended only as a screening tool, primarily for quickly assessing guideline quality and determining whether they can be adopted or adapted in other settings, and is not a substitute for some of the more complex guideline quality evaluation tools.

2022.1031

Evidence to decision frameworks enabled structured and explicit development of healthcare recommendations

In July 2022, Jose F. Meneses-Echavez et al. from the Norwegian Institute of Public Health published an article in the Journal of Clinical Epidemiology entitled "Evidence to decision frameworks enabled structured and explicit development of healthcare recommendations". The aim of this study was to identify and describe the processes suggested for the formulation of healthcare recommendations in healthcare guidelines available in guidance documents.

2022.0709

Congratulations! The number of registered guidelines exceeded 1,000+

Congratulations! The number of registered guidelines exceeded 1,000+.

2023.1127

Chinese Guideline on Risk Management of Gallstone Disease in the General Public PREPARE-2023CN968

Gallstone disease is one of the most common gastrointestinal disorders. The prevalence of cholelithiasis worldwide ranges from 10% to 20%, with a male-to-female ratio of about 1:1.25, and has shown an increasing trend in recent years. Gallstones not only lead to acute conditions like acute cholecystitis or cholangitis but can also trigger chronic diseases such as chronic cholecystitis, chronic pancreatitis, and elevate the risk of gallbladder cancer. Due to its high prevalence and substantial disease burden, gallstones have become a significant clinical and public health issue. Therefore, developing and implementing public guidelines for managing gallstone risks holds significant importance in preventing, early diagnosis, and treating gallstones. These guidelines typically encompass various aspects, including assessing gallstone risk factors, lifestyle modifications, dietary advice, medical interventions, and aim to reduce the incidence of gallstones, minimize related complications, and enhance public awareness regarding gallstone prevention and management.

2023.1127

Experts consensus on the diagnosis and treatment of refractory pituitary adenomas in China PREPARE-2023CN962

Pituitary adenoma is a prevalent intracranial neoplasm, with the majority displaying benign growth characteristics. The application of surgical intervention and/or pharmacological treatment typically results in successful remission for most patients. Nevertheless, a subset of pituitary adenomas demonstrates invasive growth patterns on imaging, exhibiting accelerated proliferation rates compared to typical tumors, and displaying resistance to conventional therapeutic modalities including surgery, pharmacotherapy, and radiation therapy. These refractory pituitary adenomas frequently exhibit early recurrence or regrowth following surgical intervention. In January 2018, the European Endocrine Society released the "European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumors and carcinomas" with the objective of establishing standardized clinical recommendations for the diagnosis, treatment, and monitoring of refractory pituitary adenoma and pituitary adenocarcinoma. Nonetheless, certain deficiencies, such as ambiguous diagnostic criteria, persist, and the management of this condition remains a global challenge. Consequently, our collaborative group will develop the "Experts consensus on the diagnosis and treatment of refractory pituitary adenomas in China" to address these issues.

2023.1127

Chinese Guideline on Risk Management of Cognitive Decline and Dementia in the General Public PREPARE-2023CN960

Cognitive decline and dementia is a current public health problem that seriously affects the quality of life, and imposes a heavy economic burden on patients' families and society. The clinical treatment effect of dementia is minimal, but changing the modifiable risk factors can effectively prevent the disease. This guideline systematically reviews and summarizes relevant evidence on the prevention of dementia and cognitive decline in the general population and high-risk groups, and forms a public guide for risk management, thereby guiding the prevention and control of cognitive decline and dementia.

2023.1126

Chinese Experts Consensus on Diagnosis and Treatment of Herpes Zoster-Associated Pain (2024) PREPARE-2023CN959

As the aging of the population accelerates, the incidence of herpes zoster-related pain（HZAP） in the population is gradually increasing, and HZRP is the most important factor affecting the quality of life of patients. In order to provide a more standardized diagnosis and treatment of HZAP, the editors of the Chinese Journal of Painology organized experts from relevant disciplines in China to conduct an in-depth discussion on the diagnosis and various aspects of HZAP with reference to domestic and foreign diagnosis and treatment guidelines, clinical research and practice, and formed a consensus among these experts.

2023.1126

Classification and Stratification of the Eighteen Anti and Nineteen Fear Theories and their Consensus among Pharmaceutical Experts for Clinical Safety Risk Assessment PREPARE-2023CN958

The theory of eighteen contraindications and nineteen contraindications for compatibility is one of the basic theories of traditional Chinese medicine. There has been controversy in the academic and clinical circles for a long time, with some views suggesting that it must be followed as a taboo, while others believe that it should not be used as a taboo and should be used according to the situation. This guideline takes a pharmaceutical perspective and integrates various available data and evidence (basic experiments, clinical experience, ancient literature, etc.) to reach a consensus on the hierarchical classification of the combination of eighteen antibodies and nineteen fears, as well as the methods used for clinical safety risk assessment.

Guidelines Interpretation

Database